Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome

Antonios Douros; Ludwig Schlemm; Juliane Bolbrinker; Martin Ebinger; Reinhold Kreutz

doi:10.1160/TH14-02-0104

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 112(02): 419-420
DOI: 10.1160/TH14-02-0104

Letters to the Editor

Schattauer GmbH

Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome

Autor*innen

Antonios Douros

¹Department of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Ludwig Schlemm

²Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Juliane Bolbrinker

¹Department of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Martin Ebinger

²Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Reinhold Kreutz

¹Department of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Abstract

Volltext

Referenzen

References
1 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
2 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
3 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
4 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
5 Pare G, Eriksson N, Lehr T. et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127: 1404-1412.
6 Samama MM, Contant G, Spiro TE. et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
7 Liesenfeld KH, Lehr T, Dansirikul C. et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 09: 2168-2175.
8 Oswald S, Groer C, Drozdzik M. et al. Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters. AAPS J 2013; 15: 1128-1140.
9 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
10 Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Pract 2013; 28: 429-436.
11 FDA - Clinical Pharmacology and Biopharmaceutics Reviews of Pradaxa. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corr-rected%203.11.2011.pdf 9-1-2010. 20-12-2013.
12 Pradaxa - German Prescribing Information. http://www.fachinfo.de/suche/fi/010963 1-1-2013. 21-2-2014.
13 Stampfuss J, Kubitza D, Becka M. et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013; 51: 549-561.
14 Xarelto - Full Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000LBL.pdf 1-7-2011. 21-2-2014.
15 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
16 Mueck W, Lensing AW, Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.